Clinical Trial Update: A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine [Phase 1]

View source ↗

Summary

Phase 1 study update evaluating how much NNC0519-0130 is in the blood of people with obesity after receiving two formulations of the drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• NNC0519-0130

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Obesity | Phase 1 | Status: COMPLETED